Clinical Trials
2 trialsNCT02321397 2016-11-04
To Demonstrate Equivalence in Analgesic Efficacy & Bowel Function Between OXN PR Higher Dose & Lower Dose Tablet Strengths in Subjects With Non-cancer or Cancer Pain
Mundipharma Research GmbH & Co KG
Phase 2/3 Completed
NCT00349518 2016-02-17
Study of Dasatinib in Imatinib Resistant or Intolerant Subjects With Chronic or Advanced Phase CML or Philadelphia Chromosome Positive ALL
Bristol-Myers Squibb
Phase 2/3 Withdrawn